A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Sponsor study identifier
Secondary identifiers
OTHER · ARIAD protocol number
interventional
39
1 country
4
Study Start
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2007
Actual (reported)Study Completion
August 2007
Actual (reported)The purpose of this study is to assess the antitumor activity of weekly ridaforolimus study treatment in participants with taxane-resistant AIPC.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
May 4, 2005
Actual (reported)May 5, 2005
Actual (reported)April 2007
Actual (reported)August 2007
Actual (reported)Best Overall Response (BOR) per Response Evaluation Criteria in Solid Tumors (RECIST)
Up to 24 months
Number of Participants Experiencing at Least One Adverse Event
Up to 25 months
Change from Baseline in Prostate-Specific Antigen (PSA)
Baseline and up to 24 months
Time to Tumor Progression (TTP)
Up to 24 months
Progression-Free Survival (PFS)
Up to 24 months
Overall Survival (OS)
Up to 24 months
50 mg of ridaforolimis intravenously over 30 minutes, weekly
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Beth Israel Deaconess Medical Center/MGH/DFCI
Boston, Massachusetts, 02215, United States
The Methodist Hospital Research Institute
Houston, Texas, 77030, United States
University of Wisconsin, Madison, WI
Madison, Wisconsin, 53792, United States
Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec;10(4):232-8. doi: 10.1016/j.clgc.2012.05.001. Epub 2012 Jun 12.
Frank Haluska, M.D.
Ariad Pharmaceuticals
39 participants (actual enrollment reported by the registry).
First Submitted
May 4, 2005
First Posted
May 5, 2005
Study Start
May 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Contact the study team to confirm eligibility.
Primary Completion
April 2007
Actual (reported)Study Completion
August 2007
Actual (reported)Last Updated
November 20, 2015
Record last verified: 2015-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: